Pure Bioscience Stock Working Capital
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Pure Bioscience fundamentals help investors to digest information that contributes to Pure Bioscience's financial success or failures. It also enables traders to predict the movement of Pure Pink Sheet. The fundamental analysis module provides a way to measure Pure Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pure Bioscience pink sheet.
Pure |
Pure Bioscience Company Working Capital Analysis
Pure Bioscience's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Pure Bioscience Working Capital | 3.61 M |
Most of Pure Bioscience's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pure Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Pure Bioscience has a Working Capital of 3.61 M. This is 99.82% lower than that of the Household Products sector and 97.18% lower than that of the Consumer Staples industry. The working capital for all United States stocks is 99.76% higher than that of the company.
Pure Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pure Bioscience's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pure Bioscience could also be used in its relative valuation, which is a method of valuing Pure Bioscience by comparing valuation metrics of similar companies.Pure Bioscience is currently under evaluation in working capital category among its peers.
Pure Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 8.00 X | ||||
| Revenue | 1.85 M | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (3.27 M) | ||||
| Net Income | (3.49 M) | ||||
| Cash And Equivalents | 511 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 239 K | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 2.02 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (2.42 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 13.36 M | ||||
| Total Asset | 4.48 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 6.14 M | ||||
| Current Liabilities | 2.54 M | ||||
| Z Score | 0.8 | ||||
| Net Asset | 4.48 M |
About Pure Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pure Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pure Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pure Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |